-
May 13: Valuation of Innovative Drugs - In Person at ISPOR 2025
-
May 13: Applied Cost-Effectiveness Modeling with R - In Person at ISPOR 2025
-
May 13: Valuing Health: The Generalized Risk Adjusted Cost-Effectiveness (GRACE) Model - In Person at ISPOR 2025
-
May 13: Using RWE to Inform the Value and Affordability Assessment of Cell and Gene Therapies - In Person at ISPOR 2025
-
May 13: - Causal Inference and Causal Diagrams in Big, Real-World Observational Data and Pragmatic Trials- In Person at ISPOR 2025
-
May 13: Using LLMs to Simplify Real-World Evidence Research - In Person at ISPOR 2025
-
May 13: A Health Economics Approach to US Value Assessment Frameworks - In Person at ISPOR 2025
-
May 13: Introduction to Applied Generative AI for HEOR - In Person at ISPOR 2025
-
May 13: Health Economic Modeling in R: A Hands-On Introduction - In Person at ISPOR 2025
-
May 13: Using Nontraditional Digital Health Platforms: A Novel Source of Real-World Evidence - In Person at ISPOR 2025
-
May 13: Cost-Effectiveness Analysis Alongside Clinical Trials - In Person at ISPOR 2025
-
May 13: Advanced Patient-Reported Outcomes - In Person at ISPOR 2025
-
Causal AI in HEOR: Beyond Predictions to Actionable Insights
-
April 23-24: Introduction to Machine Learning Methods - Virtual
-
April 9-10: Introduction to Modeling - Virtual
-
March 26-27: Introduction to Best Practices for Country Adaptations of Economic Models - Virtual
-
Challenges in Defining Elements of Value in DMD for Decision Making
-
Impact of Delayed Patient Access to Cancer Treatment
-
Defining Patient-Facing DHIs With the PICOTS-ComTeC Framework
-
February 12-13: Economic Model Review: Quality Control, Strategic Assessment and Reporting Standards - Virtual